Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors

Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors

•The affinity and potency of GR64349 for NK2 and NK1 receptors was examined.•Binding affinity was ˜1200-fold higher for NK2 than NK1 receptors.•Potency was 500-1,400-fold higher at NK2 than NK1 receptors in functional assays.•GR64349 is the most selective NK2 receptor agonist described to date. The...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience letters 2019-10, Vol.711, p.134456-134456, Article 134456
Hauptverfasser: Perdona, Elisabetta, Cavallini, Palmina, Sava, Anna, Griffante, Cristiana, Ricca, Daniel J., Thor, Karl B., Rupniak, Nadia M.J., Corsi, Mauro
Format: Artikel
Sprache:eng
Schlagworte:
GR64349
NK1 receptor
Tachykinin NK2 receptor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 134456
container_issue
container_start_page 134456
container_title Neuroscience letters
container_volume 711
creator Perdona, Elisabetta
Cavallini, Palmina
Sava, Anna
Griffante, Cristiana
Ricca, Daniel J.
Thor, Karl B.
Rupniak, Nadia M.J.
Corsi, Mauro
description •The affinity and potency of GR64349 for NK2 and NK1 receptors was examined.•Binding affinity was ˜1200-fold higher for NK2 than NK1 receptors.•Potency was 500-1,400-fold higher at NK2 than NK1 receptors in functional assays.•GR64349 is the most selective NK2 receptor agonist described to date. The affinity, potency, efficacy, and selectivity of the NK2 receptor agonist GR64349 ([Lys3,Gly8,-R-γ-lactam-Leu9]NKA(3–10)) at human recombinant NK2 and NK1 receptors was examined. In radioligand binding studies, GR64349 displaced [125I]-NKA binding to NK2 receptors with high affinity (pKi 7.77 + 0.10) but only weakly displaced [3H]-septide binding to NK1 receptors (pKi
doi_str_mv 10.1016/j.neulet.2019.134456
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6759388</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304394019305592</els_id><sourcerecordid>2280558184</sourcerecordid><originalsourceid>FETCH-LOGICAL-c463t-911ed694b696c2e25d9661a0f7f593a5dd74ad4f4f1f07a904c2326b58b022383</originalsourceid><addsrcrecordid>eNp9kctu1DAUhi0EotPCGyCUJQsy-BYn3iChqrRVq4IQrC3HPqYeEnuwnZHm7ZswvcCGlS35vxyfD6E3BK8JJuLDZh1gGqCsKSZyTRjnjXiGVqRrad3Klj5HK8wwr5nk-Agd57zBGDek4S_RESOzetaskPkaCwSzf1-Bc97o5aaDrTIMYIrf-bKvoqvOvwnOuKx0qW6nUYcqgYlj74MOpZrnSPGXDz5UN1f0j_3miiwS2JaY8iv0wukhw-v78wT9-Hz2_fSivv5yfnn66bo2XLBSS0LACsl7IYWhQBsrhSAau9Y1kunG2pZryx13xOFWS8wNZVT0TddjSlnHTtDHQ-526kewBkJJelDb5Eed9ipqr_59Cf5W_Yw7Jdq5oFsC3t0HpPh7glzU6LOBYdAB4pQVpR1umo50fJbyg9SkmHMC91hDsFr4qI068FELH3XgM9ve_j3io-kByNMfYF7UzkNS2fgZEFg_77MoG_3_G-4ApGSi9g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2280558184</pqid></control><display><type>article</type><title>Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors</title><source>ScienceDirect Journals (5 years ago - present)</source><creator>Perdona, Elisabetta ; Cavallini, Palmina ; Sava, Anna ; Griffante, Cristiana ; Ricca, Daniel J. ; Thor, Karl B. ; Rupniak, Nadia M.J. ; Corsi, Mauro</creator><creatorcontrib>Perdona, Elisabetta ; Cavallini, Palmina ; Sava, Anna ; Griffante, Cristiana ; Ricca, Daniel J. ; Thor, Karl B. ; Rupniak, Nadia M.J. ; Corsi, Mauro</creatorcontrib><description>•The affinity and potency of GR64349 for NK2 and NK1 receptors was examined.•Binding affinity was ˜1200-fold higher for NK2 than NK1 receptors.•Potency was 500-1,400-fold higher at NK2 than NK1 receptors in functional assays.•GR64349 is the most selective NK2 receptor agonist described to date. The affinity, potency, efficacy, and selectivity of the NK2 receptor agonist GR64349 ([Lys3,Gly8,-R-γ-lactam-Leu9]NKA(3–10)) at human recombinant NK2 and NK1 receptors was examined. In radioligand binding studies, GR64349 displaced [125I]-NKA binding to NK2 receptors with high affinity (pKi 7.77 + 0.10) but only weakly displaced [3H]-septide binding to NK1 receptors (pKi &lt;5). In functional studies examining increases in intracellular inositol-1 phosphate (IP-1) accumulation, calcium levels, and cyclic AMP synthesis, GR64349 was a full agonist by reference to the endogenous agonists NKA (NK2 receptors) and substance P (NK1 receptors). GR64349 increased IP-1 accumulation with 1,400-fold greater potency in cells expressing NK2 receptors (pEC50 9.10 + 0.16) than cells expressing NK1 receptors (pEC50 5.95 + 0.80). For calcium responses, GR64349 was 500-fold more potent in the assay using NK2 receptors (pEC50 9.27 + 0.26) than NK1 receptors (pEC50 6.55 + 0.16). GR64349 also stimulated cyclic AMP synthesis in both cell lines, and was almost 900-fold more potent at NK2 receptors (pEC50 10.66 + 0.27) than NK1 receptors (pEC50 7.71 + 0.41). These findings confirm that GR64349 is the most selective NK2 receptor agonist described to date.</description><identifier>ISSN: 0304-3940</identifier><identifier>EISSN: 1872-7972</identifier><identifier>DOI: 10.1016/j.neulet.2019.134456</identifier><identifier>PMID: 31445972</identifier><language>eng</language><publisher>Ireland: Elsevier B.V</publisher><subject>GR64349 ; NK1 receptor ; Tachykinin NK2 receptor</subject><ispartof>Neuroscience letters, 2019-10, Vol.711, p.134456-134456, Article 134456</ispartof><rights>2019 Elsevier B.V.</rights><rights>Copyright © 2019 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c463t-911ed694b696c2e25d9661a0f7f593a5dd74ad4f4f1f07a904c2326b58b022383</citedby><cites>FETCH-LOGICAL-c463t-911ed694b696c2e25d9661a0f7f593a5dd74ad4f4f1f07a904c2326b58b022383</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.neulet.2019.134456$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31445972$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Perdona, Elisabetta</creatorcontrib><creatorcontrib>Cavallini, Palmina</creatorcontrib><creatorcontrib>Sava, Anna</creatorcontrib><creatorcontrib>Griffante, Cristiana</creatorcontrib><creatorcontrib>Ricca, Daniel J.</creatorcontrib><creatorcontrib>Thor, Karl B.</creatorcontrib><creatorcontrib>Rupniak, Nadia M.J.</creatorcontrib><creatorcontrib>Corsi, Mauro</creatorcontrib><title>Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors</title><title>Neuroscience letters</title><addtitle>Neurosci Lett</addtitle><description>•The affinity and potency of GR64349 for NK2 and NK1 receptors was examined.•Binding affinity was ˜1200-fold higher for NK2 than NK1 receptors.•Potency was 500-1,400-fold higher at NK2 than NK1 receptors in functional assays.•GR64349 is the most selective NK2 receptor agonist described to date. The affinity, potency, efficacy, and selectivity of the NK2 receptor agonist GR64349 ([Lys3,Gly8,-R-γ-lactam-Leu9]NKA(3–10)) at human recombinant NK2 and NK1 receptors was examined. In radioligand binding studies, GR64349 displaced [125I]-NKA binding to NK2 receptors with high affinity (pKi 7.77 + 0.10) but only weakly displaced [3H]-septide binding to NK1 receptors (pKi &lt;5). In functional studies examining increases in intracellular inositol-1 phosphate (IP-1) accumulation, calcium levels, and cyclic AMP synthesis, GR64349 was a full agonist by reference to the endogenous agonists NKA (NK2 receptors) and substance P (NK1 receptors). GR64349 increased IP-1 accumulation with 1,400-fold greater potency in cells expressing NK2 receptors (pEC50 9.10 + 0.16) than cells expressing NK1 receptors (pEC50 5.95 + 0.80). For calcium responses, GR64349 was 500-fold more potent in the assay using NK2 receptors (pEC50 9.27 + 0.26) than NK1 receptors (pEC50 6.55 + 0.16). GR64349 also stimulated cyclic AMP synthesis in both cell lines, and was almost 900-fold more potent at NK2 receptors (pEC50 10.66 + 0.27) than NK1 receptors (pEC50 7.71 + 0.41). These findings confirm that GR64349 is the most selective NK2 receptor agonist described to date.</description><subject>GR64349</subject><subject>NK1 receptor</subject><subject>Tachykinin NK2 receptor</subject><issn>0304-3940</issn><issn>1872-7972</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNp9kctu1DAUhi0EotPCGyCUJQsy-BYn3iChqrRVq4IQrC3HPqYeEnuwnZHm7ZswvcCGlS35vxyfD6E3BK8JJuLDZh1gGqCsKSZyTRjnjXiGVqRrad3Klj5HK8wwr5nk-Agd57zBGDek4S_RESOzetaskPkaCwSzf1-Bc97o5aaDrTIMYIrf-bKvoqvOvwnOuKx0qW6nUYcqgYlj74MOpZrnSPGXDz5UN1f0j_3miiwS2JaY8iv0wukhw-v78wT9-Hz2_fSivv5yfnn66bo2XLBSS0LACsl7IYWhQBsrhSAau9Y1kunG2pZryx13xOFWS8wNZVT0TddjSlnHTtDHQ-526kewBkJJelDb5Eed9ipqr_59Cf5W_Yw7Jdq5oFsC3t0HpPh7glzU6LOBYdAB4pQVpR1umo50fJbyg9SkmHMC91hDsFr4qI068FELH3XgM9ve_j3io-kByNMfYF7UzkNS2fgZEFg_77MoG_3_G-4ApGSi9g</recordid><startdate>20191015</startdate><enddate>20191015</enddate><creator>Perdona, Elisabetta</creator><creator>Cavallini, Palmina</creator><creator>Sava, Anna</creator><creator>Griffante, Cristiana</creator><creator>Ricca, Daniel J.</creator><creator>Thor, Karl B.</creator><creator>Rupniak, Nadia M.J.</creator><creator>Corsi, Mauro</creator><general>Elsevier B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20191015</creationdate><title>Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors</title><author>Perdona, Elisabetta ; Cavallini, Palmina ; Sava, Anna ; Griffante, Cristiana ; Ricca, Daniel J. ; Thor, Karl B. ; Rupniak, Nadia M.J. ; Corsi, Mauro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c463t-911ed694b696c2e25d9661a0f7f593a5dd74ad4f4f1f07a904c2326b58b022383</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>GR64349</topic><topic>NK1 receptor</topic><topic>Tachykinin NK2 receptor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Perdona, Elisabetta</creatorcontrib><creatorcontrib>Cavallini, Palmina</creatorcontrib><creatorcontrib>Sava, Anna</creatorcontrib><creatorcontrib>Griffante, Cristiana</creatorcontrib><creatorcontrib>Ricca, Daniel J.</creatorcontrib><creatorcontrib>Thor, Karl B.</creatorcontrib><creatorcontrib>Rupniak, Nadia M.J.</creatorcontrib><creatorcontrib>Corsi, Mauro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neuroscience letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Perdona, Elisabetta</au><au>Cavallini, Palmina</au><au>Sava, Anna</au><au>Griffante, Cristiana</au><au>Ricca, Daniel J.</au><au>Thor, Karl B.</au><au>Rupniak, Nadia M.J.</au><au>Corsi, Mauro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors</atitle><jtitle>Neuroscience letters</jtitle><addtitle>Neurosci Lett</addtitle><date>2019-10-15</date><risdate>2019</risdate><volume>711</volume><spage>134456</spage><epage>134456</epage><pages>134456-134456</pages><artnum>134456</artnum><issn>0304-3940</issn><eissn>1872-7972</eissn><abstract>•The affinity and potency of GR64349 for NK2 and NK1 receptors was examined.•Binding affinity was ˜1200-fold higher for NK2 than NK1 receptors.•Potency was 500-1,400-fold higher at NK2 than NK1 receptors in functional assays.•GR64349 is the most selective NK2 receptor agonist described to date. The affinity, potency, efficacy, and selectivity of the NK2 receptor agonist GR64349 ([Lys3,Gly8,-R-γ-lactam-Leu9]NKA(3–10)) at human recombinant NK2 and NK1 receptors was examined. In radioligand binding studies, GR64349 displaced [125I]-NKA binding to NK2 receptors with high affinity (pKi 7.77 + 0.10) but only weakly displaced [3H]-septide binding to NK1 receptors (pKi &lt;5). In functional studies examining increases in intracellular inositol-1 phosphate (IP-1) accumulation, calcium levels, and cyclic AMP synthesis, GR64349 was a full agonist by reference to the endogenous agonists NKA (NK2 receptors) and substance P (NK1 receptors). GR64349 increased IP-1 accumulation with 1,400-fold greater potency in cells expressing NK2 receptors (pEC50 9.10 + 0.16) than cells expressing NK1 receptors (pEC50 5.95 + 0.80). For calcium responses, GR64349 was 500-fold more potent in the assay using NK2 receptors (pEC50 9.27 + 0.26) than NK1 receptors (pEC50 6.55 + 0.16). GR64349 also stimulated cyclic AMP synthesis in both cell lines, and was almost 900-fold more potent at NK2 receptors (pEC50 10.66 + 0.27) than NK1 receptors (pEC50 7.71 + 0.41). These findings confirm that GR64349 is the most selective NK2 receptor agonist described to date.</abstract><cop>Ireland</cop><pub>Elsevier B.V</pub><pmid>31445972</pmid><doi>10.1016/j.neulet.2019.134456</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0304-3940
ispartof Neuroscience letters, 2019-10, Vol.711, p.134456-134456, Article 134456
issn 0304-3940
1872-7972
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6759388
source ScienceDirect Journals (5 years ago - present)
subjects GR64349
NK1 receptor
Tachykinin NK2 receptor
title Potency, efficacy, and selectivity of GR64349 at human recombinant neurokinin NK2 and NK1 receptors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T04%3A08%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Potency,%20efficacy,%20and%20selectivity%20of%20GR64349%20at%20human%20recombinant%20neurokinin%20NK2%20and%20NK1%20receptors&rft.jtitle=Neuroscience%20letters&rft.au=Perdona,%20Elisabetta&rft.date=2019-10-15&rft.volume=711&rft.spage=134456&rft.epage=134456&rft.pages=134456-134456&rft.artnum=134456&rft.issn=0304-3940&rft.eissn=1872-7972&rft_id=info:doi/10.1016/j.neulet.2019.134456&rft_dat=%3Cproquest_pubme%3E2280558184%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2280558184&rft_id=info:pmid/31445972&rft_els_id=S0304394019305592&rfr_iscdi=true